IQ Medical Services

Theranostics is rapidly emerging as a game-changing modality in healthcare, combining the power of diagnostic imaging with targeted therapy for personalized patient care. As this innovative approach continues to evolve, it's paving the way for more precise, efficient, and personalized treatment strategies. Leverage the experience of our team of experts to bring the power of #theranostics to your clinical practice. With over 130 cyclotron projects completed worldwide, our team specializes in building programs for the needs of your patients today - and tomorrow. Get in touch with us: https://lnkd.in/dST55Ev8

The numbers speak for themselves! Over the past few years, the industry's growth has felt nothing short of exponential—and the market potential is just as impressive. With projections reaching $5.44 billion USD by 2031, the field is evolving rapidly. We're excited to witness the positive impact these advancements will have on patients around the globe! #PharmaSource

?? Crossing the world to reach a distant country, facing new cultures, and working tirelessly to meet our goals is never easy, but the warmth and kindness of the people in Indonesia made every challenge worthwhile. During our time there, we conducted IOQ and PQ for quality control equipment and training in FDG controls. A special thank you to my Padawans, Mutia Nurfaozi and Lukman Adi Nugroho – your dedication and progress throughout this project were impressive. I’m confident you’ll achieve great things in the future. Wishing you and the team continued success! I also want to express my appreciation to my colleagues Adrián Durán, Santiago A. Paz, and Alexander Grebenkin for their hard work, and to Naeleen Rosario Antigua for her support from IQ Medical Services headquarters, despite the almost 12-hour time difference. Looking forward to more collaboration in the future. #cyclotron #fdg #nuclearmedicine #Radiopharmaceuticals

Exciting news from GE HealthCare! The FDA has approved Flyrcado?(flurpiridaz-F 18) injection, a groundbreaking PET myocardial perfusion imaging agent for detecting coronary artery disease (CAD). Dr.?Jamshid Maddahi, MD, FACC, MASNC, principal investigator of the Flyrcado clinical trials, said of the approval:?“Flyrcado is the most exciting development in the field of nuclear cardiology over the past few decades. Although PET MPI as a modality enables high diagnostic accuracy as compared to SPECT MPI2, only a minority of annual PET scans in the US are PET MPI because of limited access to the currently available PET tracers—which may be addressed with the introduction of Flyrcado." #HealthcareInnovation #CardiacPET

EANM 2024 has come to a close, and what an amazing time we had in Hamburg! We were thrilled to connect with our valued customers, industry partners, and dear friends at the European Association of Nuclear Medicine annual meeting. Our team had a fantastic experience engaging with clients and attending insightful educational sessions, all aimed at learning from the vibrant nuclear medicine community. It’s always a pleasure to engage in meaningful discussions about how our modality enhances patient care and to witness the rapid advancements in the industry that are driving improved outcomes. Thank you to everyone who made this event memorable - until next year! #EANM24

It’s Nuclear Medicine and Molecular Imaging Week! Our groundbreaking advancements in nuclear medicine are transforming patient care, from early diagnosis to targeted therapy. From imaging techniques that provide unparalleled insights into the body's inner workings to therapies that deliver precise treatments to disease sites, our industry is revolutionizing healthcare. Let's continue to collaborate, innovate, and push the boundaries of what's possible. Together, we can shape the future of medicine and improve the lives of countless patients. #NMWeek #SeeItTreatItBelieveIt

As we commemorate #WorldCancerResearchDay on September 24th, let's celebrate the remarkable strides made in nuclear medicine and theranostics. These advancements, driven by relentless research, are revolutionizing cancer care. Through the development of innovative radiopharmaceuticals, we’re unlocking new possibilities for precision diagnosis and targeted treatment. Our dedication to pushing the boundaries of science reflects our unwavering commitment to improving patient outcomes and shaping a future where cancer is a treatable disease. Join us in honoring the researchers, clinicians, and innovators who are at the forefront of this medical revolution. Together, we can continue to break down barriers, accelerate discoveries, and bring hope to countless individuals affected by cancer. #cancerresearch

Excited to share a recent achievement! At?IQ Medical Services, we had the privilege of working with?Hospital Muguerza?in Monterrey, Mexico, on a key project for radiopharmaceutical production. Our team handled the installation of hot cells, QC equipment, IOQ and PQ, culminating in the process validation (PV) for FDG production. A special thanks to our project manager, Federico Díaz, whose meticulous eye was always overseeing every step of the process. A heartfelt thank you to our hosts at Hospital Muguerza for their exceptional hospitality during our stay. It made all the difference! María Patricia Acosta Mari?o Antonio De León Saray Soto Arévalo Daniela Padilla Hugo Solis This project is a significant step forward?in our mission to deliver high-quality solutions for radiopharmaceutical production. #IQMS #Healthcare #Radiopharmacy #FDG #Muguerza #Cyclotron #Quality #Projectmanagement

Excited to share a recent achievement! At?IQ Medical Services, we had the privilege of working with?Hospital Muguerza?in Monterrey, Mexico, on a key project for radiopharmaceutical production. Our team handled the installation of hot cells, QC equipment, IOQ and PQ, culminating in the process validation (PV) for FDG production. A special thanks to our project manager, Federico Díaz, whose meticulous eye was always overseeing every step of the process. A heartfelt thank you to our hosts at Hospital Muguerza for their exceptional hospitality during our stay. It made all the difference! María Patricia Acosta Mari?o Antonio De León Saray Soto Arévalo Daniela Padilla Hugo Solis This project is a significant step forward?in our mission to deliver high-quality solutions for radiopharmaceutical production. #IQMS #Healthcare #Radiopharmacy #FDG #Muguerza #Cyclotron #Quality #Projectmanagement

Ocorreu nos últimos dias 11/09/2024 e 12/09/2024 o I Simpósio de Imagem Molecular do LIM-43 do Hospital das Clínicas da Faculdade de Medicina da Universidade de S?o Paulo. Neste evento celebramos os 10 anos da obten??o da primeira imagem molecular com PET/CT utilizando biomarcador de proteína amilóide no Brasil, com especial foco na avalia??o de pacientes com processos neurodegenerativos , com destaque para a doen?a de Alzheimer. O evento contou com a participa??o de ilustres convidados nacionais e internacionais, dentre os quais destacamos o Prof. Eduardo Zimmer da Universidade Federal do Rio Grande do Sul, Profa. Danielle Macêdo Gaspar da Universidade Federal do Ceará , Prof. David Jones da Mayo Clinic, Rochester, Minnesota - Estados Unidos, Prof. Juan Fortea do Hospital de la Santa Creu i Sant Pau de Barcelona - Espanha, e o Prof. Tharick Pascoal da Universidade de Pittsburgh, Pensilvania - Estados Unidos. Tivemos a honra e oportunidade de contar com a participa??o do Prof. Marco Ant?nio Zago que é o atual Presidente da FAPESP e da Profa. Stefania Forner que é Diretora da Alzheimer’s Association nos EUA , que conversaram com os jovens estudantes e cientistas sobre as múltiplas oportunidades de funding para pesquisa. N?o poderia deixar de fazer também um especial agradecimento a toda equipe que proporcionou esse desenvolvimento nos últimos dez anos e que participou como Comitê Organizador deste evento , representados pela Profa. Daniele de Paula Faria, Prof. Artur Martins N. Coutinho , Prof. Marcelo T. Sapienza, Miriam Okamoto representando toda a equipe do CinRad, e sem esquecer nosso grande parceiro de tantos anos e que foi essencial para atingirmos juntos esse marco, Prof. Geraldo Busatto. Aproveitamos também para fazer um especial agradecimento a nossos parceiros e patrocinadores, GE HealthCare , IQ Medical Services, CMR Pharma e USP - Universidade de S?o Paulo . Nossa miss?o em estimular a pesquisa em neurociências e estimular uma brilhante gera??o de novos valores que est?o distribuídos nos diferentes departamentos da nossa Universidade e pelo Brasil afora, e reter valores que já se destacam atuando na academia continua e nos preenche de enorme orgulho e emo??o. Que venha o II Simpósio de Imagem Molecular do LIM-43 do HCFMUSP em 2026.